



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER OF PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE INDICATED BELOW.

BY: *Antette Elliott*

DATE: 8-5-05

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Patent Application of Noel Bouck, et al.	: Group Art Unit: 1636 : : :
Appln. No.:	10/603,387	: Examiner: Celine X. Qian : :
Filed:	June 25, 2003	: Attorney Docket : :
For:	METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS	: No. 053662-5018-04 :

**RESPONSE TO THE RESTRICTION REQUIREMENT**

This Response to the Restriction Requirement responds to the Restriction Requirement mailed on July 15, 2005, in the above-captioned application. This Response is being timely filed.

Responsive to the Restriction Requirement, Applicants hereby elect to prosecute the claims of Group II, claims 43-44, drawn to methods of inhibiting neovascularization of the eye. This election is made without traverse and without prejudice to the inclusion of the same or different subject matter of the non-elected claims in any later filed divisional or continuation application.

Favorable examination of claims 43-44 is respectfully requested.

Respectfully submitted,

**NOEL BOUCK, ET AL.**

by: *Gail H. Griffin*

**GAIL H. GRIFFIN**

Registration No. 51,941

MORGAN, LEWIS & BOCKIUS, L.L.P.

1701 Market Street

Philadelphia, PA 19103-2921

Telephone No.: 215-963-5000

**Direct Telephone: 215-963-5265**

Facsimile: 215-963-5001

E-Mail: ggriffin@morganlewis.com

Attorney for Applicants

August 5, 2005

(Date)